Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.7
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 11940578
Iijima Y, et al. (2002) c-Raf/MEK/ERK pathway controls protein kinase C-mediated p70S6K activation in adult cardiac muscle cells. J Biol Chem 277, 23065-75 11940578
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

T202-p - ERK1 (human)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): T202‑p, ERK1 iso2 (human): T202‑p, ERK1 iso3 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  heart
Cellular systems studied:  primary cells, tissue
Species studied:  cat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
blood pressure increase pressure overload
phorbol_ester increase
phorbol_ester RAF1 (human) inhibit treatment-induced increase dominant negative
U0126 phorbol_ester inhibit treatment-induced increase
phorbol_ester DUSP6 (human) inhibit treatment-induced increase
insulin no change compared to control
colforsin no change compared to control

Y204-p - ERK1 (human)
Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): Y204‑p, ERK1 iso2 (human): Y204‑p, ERK1 iso3 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  heart
Cellular systems studied:  primary cells, tissue
Species studied:  cat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
blood pressure increase pressure overload
phorbol_ester increase
phorbol_ester RAF1 (human) inhibit treatment-induced increase dominant negative
U0126 phorbol_ester inhibit treatment-induced increase
phorbol_ester DUSP6 (human) inhibit treatment-induced increase
insulin no change compared to control
colforsin no change compared to control

T185-p - ERK2 (human)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p, ERK2 (cow): T185‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  heart
Cellular systems studied:  primary cells, tissue
Species studied:  cat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
blood pressure increase pressure overload
phorbol_ester increase
phorbol_ester RAF1 (human) inhibit treatment-induced increase dominant negative
U0126 phorbol_ester inhibit treatment-induced increase
phorbol_ester DUSP6 (human) inhibit treatment-induced increase
insulin no change compared to control
colforsin no change compared to control

Y187-p - ERK2 (human)
Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p, ERK2 (cow): Y187‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  heart
Cellular systems studied:  primary cells, tissue
Species studied:  cat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
blood pressure increase pressure overload
phorbol_ester increase
phorbol_ester RAF1 (human) inhibit treatment-induced increase dominant negative
U0126 phorbol_ester inhibit treatment-induced increase
phorbol_ester DUSP6 (human) inhibit treatment-induced increase
insulin no change compared to control
colforsin no change compared to control

T183-p - JNK1 (human)
Modsite: AGtsFMMtPyVVtRY SwissProt Entrez-Gene
Orthologous residues
JNK1 (human): T183‑p, JNK1 iso2 (human): T183‑p, JNK1 iso3 (human): T183‑p, JNK1 (mouse): T183‑p, JNK1 (rat): T183‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  heart
Cellular systems studied:  primary cells, tissue
Species studied:  cat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
blood pressure increase pressure overload
phorbol_ester increase
insulin no change compared to control
colforsin no change compared to control

Y185-p - JNK1 (human)
Modsite: tsFMMtPyVVtRYYR SwissProt Entrez-Gene
Orthologous residues
JNK1 (human): Y185‑p, JNK1 iso2 (human): Y185‑p, JNK1 iso3 (human): Y185‑p, JNK1 (mouse): Y185‑p, JNK1 (rat): Y185‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  heart
Cellular systems studied:  primary cells, tissue
Species studied:  cat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
blood pressure increase pressure overload
phorbol_ester increase
insulin no change compared to control
colforsin no change compared to control

S2448-p - mTOR (human)
Modsite: RsRtRtDsysAGQsV SwissProt Entrez-Gene
Orthologous residues
mTOR (human): S2448‑p, mTOR (mouse): S2448‑p, mTOR (rat): S2448‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  heart
Cellular systems studied:  primary cells, tissue
Species studied:  cat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phorbol_ester increase
U0126 phorbol_ester inhibit treatment-induced increase
phorbol_ester RAF1 (human) inhibit treatment-induced increase dominant negative
phorbol_ester DUSP6 (human) inhibit treatment-induced increase
SB203580 phorbol_ester no effect upon treatment-induced increase
SB202190 phorbol_ester no effect upon treatment-induced increase
rapamycin phorbol_ester no effect upon treatment-induced increase
insulin increase
insulin RAF1 (human) no effect upon treatment-induced increase dominant negative
U0126 insulin no effect upon treatment-induced increase
SB203580 insulin inhibit treatment-induced increase
insulin DUSP6 (human) no effect upon treatment-induced increase
SB202190 insulin inhibit treatment-induced increase
rapamycin insulin no effect upon treatment-induced increase
colforsin increase
colforsin RAF1 (human) inhibit treatment-induced increase dominant negative
U0126 colforsin no effect upon treatment-induced increase
colforsin DUSP6 (human) no effect upon treatment-induced increase
SB203580 colforsin no effect upon treatment-induced increase
SB202190 colforsin no effect upon treatment-induced increase
rapamycin colforsin no effect upon treatment-induced increase

T180-p - P38A (human)
Modsite: RHtDDEMtGyVAtRW SwissProt Entrez-Gene
Orthologous residues
P38A (human): T180‑p, P38A iso2 (human): T180‑p, P38A (mouse): T180‑p, P38A iso3 (mouse): T180‑p, P38A (rat): T180‑p, P38A (salmonid): T181‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  heart
Cellular systems studied:  primary cells, tissue
Species studied:  cat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
blood pressure increase pressure overload
phorbol_ester increase
phorbol_ester RAF1 (human) inhibit treatment-induced increase dominant negative
U0126 phorbol_ester inhibit treatment-induced increase
phorbol_ester DUSP6 (human) inhibit treatment-induced increase
insulin no change compared to control
colforsin increase
U0126 colforsin no effect upon treatment-induced increase
colforsin DUSP6 (human) inhibit treatment-induced increase

Y182-p - P38A (human)
Modsite: tDDEMtGyVAtRWYR SwissProt Entrez-Gene
Orthologous residues
P38A (human): Y182‑p, P38A iso2 (human): Y182‑p, P38A (mouse): Y182‑p, P38A iso3 (mouse): Y182‑p, P38A (rat): Y182‑p, P38A (salmonid): Y183‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  heart
Cellular systems studied:  primary cells, tissue
Species studied:  cat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
blood pressure increase pressure overload
phorbol_ester increase
phorbol_ester RAF1 (human) inhibit treatment-induced increase dominant negative
U0126 phorbol_ester inhibit treatment-induced increase
phorbol_ester DUSP6 (human) inhibit treatment-induced increase
insulin no change compared to control
colforsin increase
U0126 colforsin no effect upon treatment-induced increase
colforsin DUSP6 (human) inhibit treatment-induced increase

T412-p - p70S6K (human)
Modsite: NQVFLGFtyVAPsVL SwissProt Entrez-Gene
Orthologous residues
p70S6K (human): T412‑p, p70S6K iso2 (human): T389‑p, p70S6K (mouse): T412‑p, p70S6K (rat): T412‑p, p70S6K iso2 (rat): T389‑p, p70S6K (fruit fly): T398‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  heart
Cellular systems studied:  primary cells, tissue
Species studied:  cat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
blood pressure increase pressure overloaded
phorbol_ester increase
bisindolylmaleimide phorbol_ester inhibit treatment-induced increase
wortmannin phorbol_ester no effect upon treatment-induced increase
phorbol_ester RAF1 (human) inhibit treatment-induced increase dominant negative
U0126 phorbol_ester inhibit treatment-induced increase
phorbol_ester DUSP6 (human) inhibit treatment-induced increase
SB203580 phorbol_ester inhibit treatment-induced increase
SB202190 phorbol_ester inhibit treatment-induced increase
rapamycin phorbol_ester inhibit treatment-induced increase
insulin increase
bisindolylmaleimide insulin no effect upon treatment-induced increase
wortmannin insulin inhibit treatment-induced increase
insulin RAF1 (human) no effect upon treatment-induced increase dominant negative
U0126 insulin inhibit treatment-induced increase
insulin DUSP6 (human) no effect upon treatment-induced increase
SB203580 insulin augment treatment-induced decrease
SB202190 insulin inhibit treatment-induced increase
rapamycin insulin inhibit treatment-induced increase
colforsin increase
bisindolylmaleimide colforsin no effect upon treatment-induced increase
wortmannin colforsin no effect upon treatment-induced increase
colforsin RAF1 (human) inhibit treatment-induced increase dominant negative
U0126 colforsin inhibit treatment-induced increase
colforsin DUSP6 (human) inhibit treatment-induced increase
SB203580 colforsin inhibit treatment-induced increase
SB202190 colforsin inhibit treatment-induced increase
rapamycin colforsin inhibit treatment-induced increase

T444-p - p70S6K (human)
Modsite: RFIGsPRtPVsPVkF SwissProt Entrez-Gene
Orthologous residues
p70S6K (human): T444‑p, p70S6K iso2 (human): T421‑p, p70S6K (mouse): T444‑p, p70S6K (rat): T444‑p, p70S6K iso2 (rat): T421‑p, p70S6K (fruit fly): S429‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  heart
Cellular systems studied:  primary cells, tissue
Species studied:  cat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
blood pressure increase pressure overloaded
phorbol_ester increase
bisindolylmaleimide phorbol_ester inhibit treatment-induced increase
wortmannin phorbol_ester no effect upon treatment-induced increase
phorbol_ester RAF1 (human) inhibit treatment-induced increase dominant negative
U0126 phorbol_ester inhibit treatment-induced increase
phorbol_ester DUSP6 (human) inhibit treatment-induced increase
SB203580 phorbol_ester inhibit treatment-induced increase
SB202190 phorbol_ester inhibit treatment-induced increase
rapamycin phorbol_ester no effect upon treatment-induced increase
insulin increase
bisindolylmaleimide insulin no effect upon treatment-induced increase
wortmannin insulin inhibit treatment-induced increase
insulin RAF1 (human) no effect upon treatment-induced increase dominant negative
U0126 insulin inhibit treatment-induced increase
insulin DUSP6 (human) no effect upon treatment-induced increase
SB203580 insulin inhibit treatment-induced increase
SB202190 insulin inhibit treatment-induced increase
rapamycin insulin no change compared to control
colforsin increase
bisindolylmaleimide colforsin no effect upon treatment-induced increase
wortmannin colforsin no effect upon treatment-induced increase
colforsin RAF1 (human) inhibit treatment-induced increase dominant negative
U0126 colforsin inhibit treatment-induced increase
colforsin DUSP6 (human) inhibit treatment-induced increase
SB203580 colforsin inhibit treatment-induced increase
SB202190 colforsin inhibit treatment-induced increase
rapamycin colforsin no effect upon treatment-induced increase

S447-p - p70S6K (human)
Modsite: GsPRtPVsPVkFsPG SwissProt Entrez-Gene
Orthologous residues
p70S6K (human): S447‑p, p70S6K iso2 (human): S424‑p, p70S6K (mouse): S447‑p, p70S6K (rat): S447‑p, p70S6K iso2 (rat): S424‑p, p70S6K (fruit fly): S430‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  heart
Cellular systems studied:  primary cells, tissue
Species studied:  cat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
blood pressure increase pressure overloaded
phorbol_ester increase
bisindolylmaleimide phorbol_ester inhibit treatment-induced increase
wortmannin phorbol_ester no effect upon treatment-induced increase
phorbol_ester RAF1 (human) inhibit treatment-induced increase dominant negative
U0126 phorbol_ester inhibit treatment-induced increase
phorbol_ester DUSP6 (human) inhibit treatment-induced increase
SB203580 phorbol_ester inhibit treatment-induced increase
SB202190 phorbol_ester inhibit treatment-induced increase
rapamycin phorbol_ester no effect upon treatment-induced increase
insulin increase
bisindolylmaleimide insulin no effect upon treatment-induced increase
wortmannin insulin inhibit treatment-induced increase
insulin RAF1 (human) no effect upon treatment-induced increase dominant negative
U0126 insulin inhibit treatment-induced increase
insulin DUSP6 (human) no effect upon treatment-induced increase
SB203580 insulin inhibit treatment-induced increase
SB202190 insulin inhibit treatment-induced increase
rapamycin insulin no change compared to control
colforsin increase
bisindolylmaleimide colforsin no effect upon treatment-induced increase
wortmannin colforsin no effect upon treatment-induced increase
colforsin RAF1 (human) inhibit treatment-induced increase dominant negative
U0126 colforsin inhibit treatment-induced increase
colforsin DUSP6 (human) inhibit treatment-induced increase
SB203580 colforsin inhibit treatment-induced increase
SB202190 colforsin inhibit treatment-induced increase
rapamycin colforsin no effect upon treatment-induced increase

S235-p - S6 (human)
Modsite: IAKRRRLssLRAsts SwissProt Entrez-Gene
Orthologous residues
S6 (human): S235‑p, S6 (mouse): S235‑p, S6 (rat): S235‑p, S6 (fruit fly): A234‑p, S6 (cow): S235‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  heart
Cellular systems studied:  primary cells, tissue
Species studied:  cat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phorbol_ester increase
rapamycin phorbol_ester inhibit treatment-induced increase
insulin increase
rapamycin insulin inhibit treatment-induced increase
colforsin increase
rapamycin colforsin inhibit treatment-induced increase

S236-p - S6 (human)
Modsite: AKRRRLssLRAstsK SwissProt Entrez-Gene
Orthologous residues
S6 (human): S236‑p, S6 (mouse): S236‑p, S6 (rat): S236‑p, S6 (fruit fly): S235‑p, S6 (cow): S236‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  heart
Cellular systems studied:  primary cells, tissue
Species studied:  cat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phorbol_ester increase
rapamycin phorbol_ester inhibit treatment-induced increase
insulin increase
rapamycin insulin inhibit treatment-induced increase
colforsin increase
rapamycin colforsin inhibit treatment-induced increase